BioCentury
ARTICLE | Clinical News

ACT boosted on stem cell results

October 16, 2014 3:27 AM UTC

Advanced Cell Technology Inc. (OTCBB:ACTC) held most of the gain it picked up ahead of Wednesday's online publication of data from a pair of Phase I/II trials showing visual improvements in patients treated with the company's retinal pigment epithelium (RPE) derived from human stem cells.

As published online in The Lancet, one study enrolled nine patients with dry age-related macular degeneration (AMD); the other enrolled nine patients with Stargardt's macular dystrophy (SMD). Combined, 13 of the patients treated with ACT's MA09-hRPE cells had evidence of engraftment that led to increased subretinal pigmentation. ...